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Despite recent advances in hepatic surgery, resec-
tion of the cirrhotic liver continues to be fraught
with high morbidity and mortality rates. As a result,
for many patients requiring resection of HCC the
postoperative course is complicated and the prob-
ability of cure is diminished by coexisting cirrhosis.
In this review, we discuss the characteristics
of the cirrhotic liver which make it poorly tolerant
of resection and the most common complications
that follow such surgery. The main purpose of this
paper is to review recent attempts to identify inter-
ventions that might be beneficial to cirrhotic patients
undergoing resection. These interventions include
assessment of liver reserve, advances in surgical
technique, and improvement in liver function and
regeneration.
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INTRODUCTION
In the last 20 years, surgeons appear to have
become more aggressive with hepatic resections
and as a result, the number of cases has been
steadily increasing. Tumors which were once
considered unresectable are now being ap-
proached surgically, particularly in the case of
colorectal metastases. Hepatic resection is pos-
sible in large part because of the tremendous
regenerative ability of the normal liver. In a
patient with a normal liver, up to 75% of the
liver mass can be safely resected, and mortality
rates of approximately 5% or less are possible
[1].
Resection of the cirrhotic liver, however,
presents a difficult problem and until recently,
cirrhosis was considered a contraindication for
hepatic resection. Mortality rates of 20-50% are
commonly quoted, despite careful preoperative
workups and rejection of large numbers of
patients who are medically unfit or have lesions
that are considered unresectable [2, 3].
The most common indication worldwide for
hepatic resection is hepatocellular carcinoma
(HCC), which constitutes approximately 90% of
all malignant primary liver tumors. Depending
on the geographic location, 50-85% of patients
with HCC have associated cirrhosis [4, 5]. Con-
versely, 10-20% of patients with cirrhosis from
any etiology, will go on to develop HCC [3, 6].
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Thus, the majority of patients who require
resection also have cirrhosis or impaired liver
function. An increased ability to safely perform
resection in these patients should also lead to an
increase in the surgical cure rate of hepatic
malignancies, both primary and metastatic.
rently the subject of numerous investigations,
but increased levels of circulating growth in-
hibitors such as ammonia, mercaptans, and
GABA, rather than a paucity of growth stimu-
lators is thought to be operative [9, 10].
THE CIRRHOTIC LIVER
There are a number of factors that make it
difficult for a cirrhotic patient to tolerate resec-
tion, including poor functional reserve, impaired
regeneration, elevated portal venous pressures,
and the characteristics of the patient population
undergoing resection.
Reduced Function
The removal of functional liver tissue from an
organ that already has marginal function can
lead to many complications. If insufficient func-
tioning hepatic parenchyma remains after resec-
tion, the patient will likely develop liver failure,
which is the leading cause of death postopera-
tively. It is crucial to be able to resect a sufficient
amount of liver to effect a cure, while leaving
enough healthy liver to ensure survival. A mini-
mum amount of liver function appears to be
crucial to sustain life.
Impaired Regeneration
Unlike the normal liver, which, within 3-12
months can regenerate to its original size and
function, even after 80% resection, the cirrhotic
liver has impaired regenerative ability. Indeed,
until recently, the cirrhotic liver was thought
to be unable to regenerate [7]. However, we now
know that while it is able to regenerate some-
what, the cirrhotic liver is greatly impaired both
in rate and extent of regeneration [8]. The reason
for this impaired regenerative capacity is cur-
Portal Hypertension
Portal hypertension poses a number of problems
in cirrhosis. Principal amongst these is that the
rate of blood loss is accelerated and hemostatic
mechanisms are often unable to overcome
venous bleeding because of the high pressures.
In addition, numerous venous collaterals are
formed in an attempt to bypass the high re-
sistance of the intrahepatic vasculature. These
collaterals are particularly prominent in the area
of the porta hepatis, making dissection difficult
and hazardous. This likely contributes to the
high mortality rate noted in the performance
of cholecystectomy in cirrhotic patients [11, 12].
Kanematsu noted an immediate increase in
portal pressures at the time of major hepatic
resection. Smaller (segmental and subsegmental)
resections, on the other hand, did not lead to
significant increases in pressure. Morbidity and
mortality did not, however, correlate with the
degree of increase in portal pressure [13].
Patient Population
The majority of patients requiring hepatic resec-
tion (particularly alcoholics with HCC), are in
their 5th to 7th decades of life and will often
have associated medical problems. Moreover,
there is evidence to suggest that a number of
hepatic changes are seen with aging, including
decreased Reticuloendothelial System (RES)
function [14], decreased regeneration, and im-
paired mitochondrial enzyme activity [15]. Care-
ful preoperative assessments and vigilant
post-op monitoring are essential in managing
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RISKS AND COMPLICATIONS OF LIVER
RESECTION IN CIRRHOSIS
Hepatic resection in non-cirrhotic patients can
be accomplished with relative safety, and a
morbidity of under 5% for elective lobar resec-
tions is commonly achievable in most centers.
The main risk factor appears to be associated
medical illness [16].
On the other hand, the risks and complica-
tions associated with resections in cirrhotic
patients are more complex. The extent of re-
section and degree of baseline functional impair-
ment appear to be the main independent risk
factors. Other factors, such as bleeding tendency,
ascites, anemia, and hypoalbuminemia appear
to be dependent on these two variables [17, 18].
The serious complications that these patients are
prone to develop are hepatic failure, sepsis, and
bleeding, which can largely be attributed to in-
sufficient hepatic function.
Cirrhotic patients are prone to these complica-
tions when undergoing surgery of any kind, not
only hepatectomy. Doberneck examined cirrho-
tic patients undergoing a variety of operations
including intraabdominal, genitourinary, and
orthopedic procedures [19]. An overall compli-
cation rate of 47.1% along with a mortality rate
of 19.6% was seen. Liver failure occurred in 43
patients, sepsis in 19 patients, and bleeding in 9
out of 102 patients.
In 1985, Yanaga noted intraperitoneal septic
complications in 16 of 103 cirrhotic patients
undergoing hepatic resection [20]. On the other
hand, only 3 of 46 patients without cirrhosis
developed sepsis. The cause of death in the 13
patients that died was noted as progressive liver
failure.
Another large series identified a mortality rate
of 8.9% and a complication rate of 31.7% among
101 cirrhotic patients undergoing major and
subsegmental resections for HCC [21]. Sepsis
was seen in 4 of 102 patients, bleeding in 10
patients, and liver failure in 10 patients. The
lower mortality rate seen here can be explained
by the fact that over half the resections were
subsegmental and a large number were done for
palliation only.
More recently, Fan in 1995 published results
of a series of 54 cirrhotic patients undergoing
major resections [22]. Seven deaths occurred for
a mortality of 13%, and serious complications
were seen in 50%. Sepsis complicated the early
postoperative course in 18 patients, while ex-
cessive bleeding was seen in 4 patients. No
mention was made of the incidence of liver
failure.
Hepatic Failure
The term "hepatic failure" does not have a
precise definition and as a result, the reported
incidence of this complication varies widely.
Liver failure is, however, consistently quoted as
the most common cause of death in cirrhotic
patients early in the postoperative period. One
author has proposed that hepatic failure in-
cludes progressive jaundice, ascites, and ence-
phalopathy, in addition to rapidly escalating
liver function studies [14]. Liver failure can also
result in insufficient metabolic, synthetic, and
immune function, predisposing to the other
complications of encephalopathy, jaundice, hy-
poalbuminemia, hypoglycemia, and sepsis.
If after estimating post-operative liver func-
tion, it appears that insufficient liver function
will remain, it is essential to reduce major re-
sections, by considering segmentectomy or even
subsegmental resection. The most precise means
of estimating post-operative liver function is
discussed later in this review.
Sepsis and ARDS
Cirrhotic patients undergoing resections are
predisposed to infection, both locally and
systemically. This is likely related to the loss of
RES function due to resection [14].
In Yanaga’s study of 149 patients under-
going resection, most of whom were cirrhotic,288 M.A..J. MOSER et al.
perioperative variables associated with Intraper-
itoneal Septic Complications after Hepatectomy
(IPSCH) [20] were examined. Risk factors iden-
tified included right lobectomy, age greater than
65 years, operation time greater than 5 hours,
blood loss > 3000mL, and postoperative bleed-
ing requiring reoperation. Notably, the risk of
IPSCH did not correlate with preoperative liver
function tests nor with the presence of cirrhosis.
The authors postulated that this relates to the
fact that more limited resections were carried
out in cirrhotic patients.
The liver’s role in filtering blood prior to entry
into the lungs may in part explain the increased
risk of ARDS following surgical resection of
cirrhotic livers [14].
Bleeding
The factors predisposing the cirrhotic patient to
bleeding are multiple and have been studied
extensively. First of all, decreased hepatic
synthetic function leads to low levels of clotting
factors. The result is an abnormal PT/PTT. Due
to the short half life of clotting factors (most
under 1 day), PT is a sensitive indicator of acute
changes in liver synthetic function [11].
In addition, thrombocytopenia, associated
with splenomegally, is often seen with chronic
liver disease. Nonetheless, platelet counts rarely
drop to low enough levels to contribute primar-
ily to bleeding.
Portal Hypertension is also a factor in in-
creased bleeding and collateral neovascularisa-
tion makes dissection difficult, particularly in
the area of the porta hepatis. The classic paper
by Schwartz in 1981 describes massive bleeding
in 18 of 33 patients who underwent cholecys-
tectomy or an operation for bile duct obstruc-
tion, despite the presence of normal coagulation
profiles in approximately half the patients [12].
On the other hand, among patients undergoing
cholecystectomy at the same time as a portal
decompressive procedure, significant bleeding
occurred in only one of 7 patients [12]. These
findings emphasize the role elevated portal
pressures play in contributing to bleeding asso-
ciated with biliary tract surgery.A number of stu-
dies have examined the role of intraoperative
Vasopressin as a means of decreasing portal pres-
sure and thereby limiting perioperative bleeding
problems. During shunt operations, Sirinek et al.,
reported a 28% decrease in portal pressure with
Vasopressin, which was associated with a de-
crease in blood loss, and a shorter operating time
[23].
Over the last 20 years, the existence of a
fibrinolytic state as well as the extent of its
contribution to the problem of operative and
postoperative blood loss has been debated.
When properly diagnosed, bleeding associated
with a fibrinolytic state has been successfully
controlled with the careful use of aminocaproic
acid [12]. Another antifibrinolytic is Aprotinin
(Trasylol(R)), a serine protease inhibitor which
inhibits plasmin and kallikrein. It has been used
successfully as an antifibrinolytic agent in car-
diac surgery and liver transplantation [24], and
may similarly be beneficial to cirrhotic patients
undergoing resection.
It is crucial to correct hemostasis preopera-
tively and to monitor hemostatic function closely
postoperatively. Recent advancements in criti-
cal care have contributed significantly to the
decrease in bleeding complications [25].
POSSIBLE INTERVENTIONS
There are a number of approaches that can be
undertaken to improve the outcome of cirrhotic
patients undergoing hepatic resection:
1. Optimization of liver function and structure
preoperatively.
2. Careful preoperative estimation of the extent
of resection possible to allow for adequate
postoperative hepatic function.
3. Advancements in surgical techniques.
4. Enhancement of post-operative hepatic re-
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5. Perioperative monitoring and management of
nutritional, clotting, septic, and fluid balance
problems.
ASSESSMENT OF HEPATIC RESERVE
A reliable estimate of liver function is essential
in planning resection in patients with impaired
hepatic function. Most importantly, a method of
estimating post-operative function could sug-
gest how much resection is feasible, if any. Many
systems and tests have been devised to evaluate
liver function; many are impractical in a clinical
setting, and few are in common use today.
Serum Liver Panel
Aside from one report suggesting that elevated
serum bilirubin preoperatively correlates with
poor outcome from resection [26], there is agree-
ment that bilirubin, Aspartate Aminotransferase,
and alkaline phosphatase levels preoperatively
do not provide a reliable estimate of hepatic
reserve and are not useful in gauging prognosis
after liver resection [27].
Indocyanine Green (ICG) Retention
and Clearance
ICG is a safe, nontoxic dye that is bound to
albumin and is cleared almost exclusively by the
liver. The rate at which ICG is cleared from the
blood after intravenous injection is a measure
of hepatic blood flow. ICG retention after 15
minutes, a variation of the test, can be done at
the bedside. Both tests have been shown by
several authors to be sensitive measures of liver
impairment, and have been used in conjunction
with other tests to better assess liver resection
and estimate post resectional function [28].
In Fan and Lai’s multivariate analysis of 54
cirrhotic patients, preoperative ICG clearance
was the only useful preoperative measure in
predicting postoperative liver failure. Discrimi-
nant analysis further revealed that an ICG
clearance of 14% most reliably separated survi-
vors and non-survivors [22]. In a similar way,
ICG15 was one of the major factors in Yamana-
ga’s regression equation [17], which will be
discussed later.
Recently, Scudamore looked at preoperative
tests in a similar fashion on 22 cirrhotic patients
undergoing resection [29]. Again, ICG clearance
was the only significant factor in predicting
postoperative liver failure. Using discriminant
analysis, the critical ICG clearance was found to
be 5 ml/min/kg. It was suggested that patients
whose ICG clearance is lower than the critical
level should not undergo hepatic resection.
Overall, ICG clearance and ICG retention are
relatively simple and safe tests, and appear to be
the most reliable assessments of liver functional
reserve currently available.
Cytochrome A (+A3) Assay
of Mitochondria
This test is based on the fact that hepatocytes
require enhancement of phosphorylative capa-
city of mitochondria in order to undergo re-
generation. When respiratory carriers such as
+ a3 are reduced, this enhancement cannot occur
and regenerating processes are impaired. Pa-
tients with reduced cytochrome a show a high
rate of complications (80%) and mortality (40%)
associated with formal lobectomy. It has been
suggested that these patients should have the
extent of resection reduced or the operation
avoided if possible. A disadvantage to the test is
that 4-a3 levels must be obtained from a liver
biopsy specimen [15]. Since the initial report in
1973, little has been done to pursue this test as a
means of assessing hepatic reserve preopera-
tively.
198Au- Colloid Clearance
Another means of assessing liver function based
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clearance of gold colloid by the liver. This
technique is based on the rate of labeled colloid
uptake by Kupffer cells as measured by a
gamma camera in many small individual sec-
tors. Using computerized techniques, a blood
flow index (KLAu) can be calculated and it is
possible to estimate with considerable accuracy
what KLAu will be when certain "sectors" of
liver tissue are removed. An estimated post op
KLAu of less than 50 is predictive of a poor
outcome and increased mortality [30].
Combination of Measures
Based on the concept that a certain quantity and
quality of liver tissue is required to sustain life,
Yamanaka and colleagues have developed a
combination of measures to preoperatively pre-
dict the volume and function of the liver fol-
lowing partial hepatectomy.
In their hands, quantity of remaining liver was
estimated from CT scan, including volume of
parenchyma to be removed and volume remain-
ing, while excluding volume of tumor, which
constitutes non-functioning tissue. These esti-
mates correlated strongly with actual volumes of
the surgical specimens. Finally, Parenchymal
Hepatic Resection Rate (PHRR) is calculated
to more accurately represent the percentage




The quality of liver or liver function is assessed
by ICG retention after i5 minutes.
When the 38 patients in their study were
classified based on PHRR and ICGls, a linear
separation was seen between survivors and non-
survivors [31].
A year later, the same group formulated a
multiple regression equation for prediction of
postoperative liver failure [5]. They examined 17
variables and found the strongest associations
with PHRR, ICG15, and patient age, which lent
support to their concept of ’quantity and
quality’. The regression equation was:
PS -84.6 + 0.93PHRR + 1.11 ICG15 + AGE
The equation provides a ’prognosis score’
(PS); scores greater than 50 are highly predictive
of death from liver failure.
This same group has recently published a
prospective study describing 10 years experi-
ence using this equation on 434 patients un-
dergoing liver resection, most of whom had
cirrhosis [13]. Patients with scores greater than
55 were classified as high risk, whereas scores of
45- 55 were considered borderline. The objective
was to obtain a score of 45 or less (the low risk
group) by changing the resection from a lobec-
tomy to a lesser resection whenever possible. For
patients with scores greater than 50, medical
management was strongly advised.
Overall, 129 patients had the extent of their
resections reduced preoperatively. Among the
seven patients who had scores higher than 55,
six died within 3 months post op, all due to liver
failure. Among patients with scores under 45,
a mortality of 7.3% was achieved (26/357) for
HCC, while none of 49 patients with metastatic
cancer died. The group of patients with PS of 45
to 55 were identified as borderline; in this group,
a striking difference in Oral Glucose Tolerance
Test (OGTT) results was noted between survi-
vors and non-survivors. On this basis, the
authors suggest placing patients with borderline
scores and linear OGTT curves into the high-risk
category as a refinement of their assessment
technique. Resection may be considered rela-
tively safe for patients in the borderline zone
who have parabolic OGTT curves.
SURGICAL CONSIDERATIONS
The development of subsegmental resection
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ultrasound (IOUS) have been significant ad-
vancements in liver surgery. Subsegmental
resection is particularly helpful in resection of
cirrhotic liver to minimize the extent of resection
of non-diseased liver. Using IOUS, the tumor is
identified as well as its relation to surrounding
vessels. A needle is placed in the branch of the
portal vein supplying the tumor and ICG or
indigo carmine dye is injected to demarcate the
area to be resected. Dissection along the demar-
cation line allows for the resection to be carried
out with minimal bleeding [32]. IOUS is helpful
in assessing the feasibility of resection as well as
obtaining an accurate assessment of the extent
of disease [32]. Relationships of the tumor to
vascular structures as delineated by IOUS
influenced the choice of operative procedure in
22 of 45 patients (49%) in one study [33] and 20
of 30 patients (67%) in another [34]. In the case of
surgery for metastatic disease, IOUS was more
sensitive than CT or preoperative ultrasound in
detecting occult metastases under I cm in size
[33].
Other interventions have also been proposed,
particularly methods to decrease the bleeding
complications associated with cirrhosis. Techni-
ques of occluding hepatic inflow (Pringle man-
euver) and outflow are being investigated as
means of reducing blood loss in healthy livers
[16]. However, the ability of cirrhotic liver to
tolerate blood flow occlusion has not yet been
fully elucidated and may limit its use in this
situation [35]. In a pilot study involving 15
patients with cirrhosis who had hepatic inflow
occlusion (Pringle maneuver) for 9-32 minutes
during hepatic resection, a significant decrease
in blood loss was achieved compared to a
similar group of 15 patients operated on without
the use of blood flow occlusion. In addition, no
hemodynamic complications resulted and no
changes were seen in liver function studies,
followed for up to 3 weeks post op in the blood
flow occluded group [36]. Overall, the cirrhotic
liver appeared to tolerate ischemia better than
originally thought, possibly due in large part to
hepatic venous backflow. A later study looked at
44 cirrhotic patients and the use of inflow
occlusion for 8 to 46 minutes without adverse
effects, whereas simultaneous inflow and out-
flow occlusion, while it resulted in less blood
loss, was associated with liver enzyme changes
consistent with ischemia. At the end of the
study, the need for a future prospective study
was emphasized [37].
A number of techniques have been developed
to aid in the hemostatic dissection of the liver,
including the Cavitron ultrasonic aspirator
(CUSA), the Argon beam, and YAG laser. Few
of these have been subjected to prospective
studies, particularly in the setting of cirrhosis.
The CUSA may be impractical in cirrhotic liver,
because the parenchyma is of a rubbery texture,
closely resembling that of the major blood
vessels. On the other hand, a water-jet dissector
could be useful to decrease blood loss in
cirrhotic patients [38, 39].
The use of the Lin liver clamp [40] is con-
troversial, particularly in cirrhosis, because of
the inhomogeneous texture and fibrous scarring
present [16]. In addition, the neovascularisation
associated with portal hypertension makes its
application difficult and hazardous at times. A
transdiaphragmatic approach to the right lobe
has been advocated by one group to avoid the
hypervascular porta hepatis area [41]. Using this
approach, a decrease in blood loss and post op
complications was achieved. On the other hand,
the choice of a thoracic incision needs to be
made carefully, because it too has a high rate of
complications; also, hepatic inflow occlusion





In cirrhosis, repair and regeneration in response
to an insult result in fibrosis and architectural292 M.A.J. MOSER et al.
distortion of both parenchymal and vascular
elements [42]. The precise relationship between
fibrosis and liver function or regenerative
potential requires further investigation [43]. It
is well known that the advanced cirrhotic liver
possesses poor regenerative ability. As a result, a
number of studies have attempted to reduce or
prevent fibrosis and improve regeneration [44].
Colchicine has been studied for many years
and its effects have been well documented. This
agent acts on many phases of collagen metabo-
lism including decreased production and secre-
tion, while increasing collagenase production
[45]. In addition, colchicine affects lymphocyte
and monocyte activity and these cells may
contribute to the stimulation of myofibroblasts
in the liver. The actions of colchicine appear to
be on the incorporation of proline and inde-
pendent of impairment of prolyl hydroxylase
activity [44]. In vivo studies in the rat have
suggested decreased fibrinogenesis and im-
proved liver function [46].
A randomized controlled trial of Colchicine
followed 100 patients for 3 to 14 years [47].
Histological improvement was suggested in the
group receiving colchicine. Survival was also
improved. Five year survival rates were 75% in
the colchicine group versus 34% in the placebo
group, while ten-year survival rates were 56%
and 20% respectively. Long-term colchicine
improved patient survival in cirrhosis, by pre-
venting and reversing fibrosis. However, the
colchicine and placebo treated groups were not
well matched, and drop out rates were high.
Moreover, it is not clear whether the beneficial
effects can occur rapidly enough to be practical
for preoperative preparation.
Pentoxifylline is a methylxanthine which has
been used for years to improve blood flow in the
lower limbs of patients with intermittent clau-
dication. In a number of studies involving
animal models of cirrhosis, pentoxifylline has
been shown to decrease hepatic fibrinogenesis
and improve serum liver function tests [48, 49].
The mechanism involved is that of inhibition of
Platelet-Derived Growth Factor (PDGF) induced
fibrinogenesis, possibly by interfering with post-
receptor second messenger signals involving the
adenosine receptor. Other studies have shown a
protective effect of adenosine in a rat model of
cirrhosis [50].
Ciprofloxacin, in addition to its antibiotic
actions, has intrinsic GABA receptor blocking
properties [9]. GABA receptors and transport
proteins have been demonstrated on the surface
of hepatocytes [51] and it has been shown that
GABA has an inhibitory effect on hepatic
regeneration [52]. In addition, elevated GABA
levels are a common finding in the setting of
acute or chronic liver disease [53]. Studies have
shown that ciprofloxacin through its GABA
blocking properties, enhances regeneration and
protects against ethanol- and galactosamine-
induced inhibition of regeneration [54]. This
effect was independent of the antibiotic effect on
the intestinal flora [55].
A recent study has demonstrated a reduction
in the degree of fibrotic change in cirrhosis, after
a 4 week course of Ciprofloxacin in the CC14
induced cirrhotic rat model. In addition, liver
function as measured by serum ALT was
improved [56]. The effects on regeneration,
fibrosis, and hepatocyte viability may be bene-
ficial to the cirrhotic liver undergoing partial
hepatectomy. Such studies are currently under-
way.
Traditional Chinese Herbal Remedies have been
used for centuries in the treatment of liver
disease. While many formulations exist, few
have been well studied in a controlled scientific
fashion. One specific formulation which con-
tains many ingredients, including boiled turtle
shell, leech, pangolin scales, and ginseng was
found in a prospective, controlled trial to have a
beneficial effect on the extent of hepatic fibrosis
in a rat model of cirrhosis [56]. Fibrosis and
architectural distortion appeared to be reversed
almost to normal. The mechanism of action
involved and which of the components is active
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Hepatocyte Growth Factor (HGF) was first
discovered in 1982 and is now considered the
most potent stimulator of DNA synthesis in
hepatocytes [57]. The many effects of HGF in
vitro have been well documented; these include
increased DNA synthesis, cell motility, and
angiogenesis [58]. A favorable in vivo effect on
regenerative activity has been shown in the
mouse [59], rat [60], and dog [61]. These effects
were seen not only after partial hepatectomy,
but also in resting, healthy liver, as well. In other
words regeneration occurred with HGF as the
sole stimulus, whereas most other studies of
liver growth factors only show an improvement
in regeneration after a stimulus such as hepatic
injury or partial hepatectomy.
The effects of HGF in vivo in the setting of
cirrhosis require further study [62]. Moreover,
its action is not specific, to the liver; similar
effects have also been demonstrated in the lung,
skin, kidney, and stomach [62]. High serum
levels of HGF are seen in patients with cirrhosis
or fulminant hepatic failure [63], and it is pos-
sible that the cirrhotic liver is relatively unre-
sponsive to HGF.
Portal Venous Embolization
Because of the dual blood supply to the liver
(portal vein and hepatic artery), ligation of one
blood supply is possible with less risk of
infarction than in tissues with blood supply
from a single vessel. In a rat model that dates
back to 1920, ligation of one main portal venous
branch led to atrophy of the lobes supplied by
the branch. Of note, the other, non-ligated lobes
were stimulated to hypertrophy [64]. Since then,
the importance of hepatotrophic factors found in
portal blood has been well established [65].
This intervention has particular relevance to
the treatment of hepatic malignancies, which, as
discussed, commonly coexist with cirrhosis.
Portal Branch Ligation (PBL) could cause atro-
phy of the affected lobe containing tumor and at
the same time, prime the remaining liver to
regenerate, thereby facilitating resection and
improving cure rates. A further advantage is
the limitation of portal tumor emboli which may
occur at the time of surgery [66].
The usefulness of PBL as a preoperative
intervention has been demonstrated in studies
from Japan, where the incidence of HCC is high.
The procedure of Portal Venous Embolization
(PVE) involves injecting embolic material into
one or more portal vein branches via a percuta-
neously guided catheter. Once experience is
gained, this procedure can be done with relative
safety [67]. One study has shown an improve-
ment in survival and RES function in non-
cirrhotic rats [68]; the same has not been shown
in an animal model of cirrhosis.
Early clinical experience with this treatment
modality in cirrhotic patients have been promis-
ing with significant hypertrophy of remaining
lobes, and good anticancer effect [69].
Postoperative Improvement
in Regeneration
Transforming Growth Factor Alpha (TGF-alpha) is
a cytokine involved in hepatic regeneration.
Kokudo et al., studied the effect of TGF-alpha
on liver regeneration after hepatectomy in CC14
induced cirrhosis in the rat [70]. Regeneration in
cirrhotic rats as measured by 3[H]-Thymidine
incorporation was markedly impaired after
hepatectomy. Cirrhotic rats treated with TGF-
alpha, however, achieved regeneration compar-
able to that in non-cirrhotic rats. TGF-alpha had
no effect on regeneration in non-cirrhotic liver.
This study suggests that there is a relative de-
ficiency of TGF-alpha in cirrhotic liver; whether
this is due to decreased production, receptor
downregulation, or the presence of competitive
inhibitors will require further investigation.
Putrescine is a polyamine not only involved in
hepatic regeneration, but also the growth of
many tissues. Putrescine and the other poly-
amines appear to be essential for liver regenera-
tion to take place [71]. Furthermore, the addition294 M.A.J. MOSER et al.
of exogenous putrescine was shown to enhance
regeneration in models of acute liver disease
[72]. Thus, a study was undertaken to determine
the effect of putrescine at doses of 1, 10, and
100mg/kg given before and after partial hepa-
tectomy in a rat model of cirrhosis. Nonetheless,
no effect on regeneration was seen as measured
by DNA synthesis or ODC activity. Part of this
lack of effect could be due to the lack of change
in hepatocyte putrescine levels achieved [73].
Unfortunately, excessive regenerative activity
could actually contribute to impaired liver func-
tion and lead to liver failure in the post operative
period. This was suggested by Ito [74] who
examined the relative expression of housekeep-
ing and regeneration genes in a rat model fol-
lowing 70% hepatectomy. The housekeeping
genes studied, including albumin and ornithine
transcarbamylase (OTC), were significantly de-
pressed at 24 hours after hepatectomy, at a time
when accelerated DNA synthesis was beginning.
This corresponded to a peak in the transcription
of the oncogenes c-fos, c-myc and p53. The
authors speculate that regenerating hepatocytes
undergo dedifferentiation and as a result, cannot
participate in liver synthetic functions. This is
proposed as a putative cause for postoperative
liver failure after resection. Thus augmenting
regeneration may not actually be as beneficial in
practice as it is in theory. Further studies
examining dedifferentiation and the optimal
timing to induce regeneration are required.
SUMMARY
Liver resection in the setting of cirrhosis is not
an uncommon situation, especially in the treat-
ment of hepatocellular carcinoma, and the
coexistence of cirrhosis seriously limits curabil-
ity. Morbidity and mortality rates are unaccep-
tably high in cirrhotic patients and a number
of factors are likely responsible, including marg-
inal hepatic function, portal hypertension, and
impaired regeneration. Severe complications
contributing to the high mortality include
post operative liver failure, sepsis, and bleed-
ing. Many studies over the last 10 years have
TABLE Morbidity and mortality associated with liver resection in cirrhosis: several large reports
Author Patients Complications Complications* Mortality*
(year) Liver failure* Bleeding* Sepsis*
cirrhosis
Doberneck (1982) various surgeries 43 9 19 48 20
(n 102) (42.2) (8.8) (18.6) (47.1) (19.6)
Yanaga (1985)
2 cirrhosis 13 NR 16 29 11
(n= 103) (12.6) (16.8) (28.2) (10.6)
Nagasue (1985) cirrhosis and 10 10 4 32 9
HCC
(n 101) (9.8) (9.8) (4.2) (31.7) (8.9)
Bismuth (1986)
4 cirrhosis and 15 NR NR 20 5
HCC
(n 35) (42.9) (47.2) (14.3)
Gozetti (1987) cirrhosis 3 NR NR 4
(n 25) (12.0) (4.0) (16.0)
cirrhosis, major
Fan (1995) resections NR 4 18 27 7
(n 54) (7.4) (33.0) (50.0) (13.0)
Numbers in parentheses represent percentages.
NR Not Reported.
Am. J. Surg., 146, 306-309.
Ann. Surg., 203(2), 148-152.
Surgery, 99(6), 694-701.
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Int. Surg., 72, 82-86.
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examined means of improving outcome after
hepatic resection in cirrhosis. Preoperative as-
sessment of liver function and determination of
the extent of resection that can be tolerated have
been studied and as a result, much has been
learned. Intraoperative ultrasound and subseg-
mental resection appear to be beneficial surgical
techniques, while the technique of hepatic in-
flow/outflow occlusion is being investigated for
its applicability in the setting of cirrhosis. Portal
venous embolization, which aids in promoting
atrophy of the diseased lobe and regeneration
of the, remaining liver could in principle be
particularly helpful in the preparation of cirrho-
tic patients undergoing hepatic resections. Basic
research is also underway, searching for ways of
improving liver function preoperatively as well
as augmenting regeneration postoperatively-a
number of candidates have been identified but
few have been subjected to the rigors of clinical
trials. While a number of advancements have
allowed a slight increase in survival, many
approaches remain to be explored in an attempt
to reduce the high morbidity and mortality of
liver resection in cirrhosis and increase the cure
rate of hepatic malignancies.
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